Niclosamide is an FDA-approved antihelminthic drug that suppresses glycemia [9]; this drug has also been reported to inhibit cancer malignancy through various mechanisms, including Wnt/β-catenin [24], mTORC1 [25], STAT3 [26], NFκB [27], S100A4 signaling [28], and other signaling pathways [29,30]. This evidence concerns the gene S100A4 and cancer.